Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01841736 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
A Phase 2 study of Metastatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Tumor G1, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
- 20
- Study locations
NCT01841736 is a Phase 2 study of Metastatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Tumor G1 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 171 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT01841736, a Phase 2 study of Metastatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Tumor G1, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Echocardiography Test
- OTHER Laboratory Biomarker Analysis
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente South Bay - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Kaiser Permanente West Los Angeles - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Palo Alto Medical Foundation Health Care - Palo Alto
- Stanford Cancer Institute Palo Alto - Palo Alto
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Riverside - Riverside
Alaska
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2013-09-20 |
| Est. Completion | 2026-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01841736
The ClinicalTrials.gov registry entry for NCT01841736 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Metastatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT01841736 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT01841736 about?
NCT01841736 is a clinical study titled "Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors". This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01841736?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2013-09-20. Estimated completion is 2026-09-10.
What conditions does trial NCT01841736 study?
This clinical trial studies the following conditions: Metastatic Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor.
What interventions are being tested in trial NCT01841736?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Echocardiography Test (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01841736?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01841736 being conducted?
This trial has 20 study locations across Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Neuroendocrine Tumor
All registered trials for this condition
Metastatic Digestive System Neuroendocrine Tumor G1
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.